| Development of coronary artery stenosis in a patient with metastatic renal ... - 7thSpace Interactive (press release) |
|
|
7thSpace Interactive (press release) Tyrosine kinase inhibitors (TKIs) are currently approved for the treatment of metastatic renal cell carcinoma (mRCC). The cardiotoxic effects of sorafenib and sunitinib may cause hypertension, left ventricular ejection fraction (LVEF) dysfunction |